The transcriptional activation property of AML1/ETO on AML1/ETO-AML1 complex bound genes is potentiated through the recruitment of AP-1. (A) c-Jun, a surrogate mark for AP-1, binds to the AML1/ETO-activated genes, but not to the AML1/ETO-repressed genes. ChIP was performed with anti-c-Jun antibody. The detailed ChIP-qPCR values can be found in supplemental Figure 9. (B) Validation for the coexistence of AML1/ETO and c-Jun on the promoter regions of AML1/ETO-activated genes through re-ChIP assays. ChIP products of the first indicated antibodies from Kasumi-1 cells were subjected to immunoprecipitation using the second indicated antibodies. NC, negative control. (C) The expression level of AML1/ETO-activated genes (CALM2, DUSP6, and PADI3) is decreased on SR11302 (AP-1 inhibitor) treatment. AML1/ETO-repressed genes (PARVG, NKG7, and IL6R) were used as negative controls. Error bars in B and C represent the SD of triplicate measurements. (D) AML1/ETO interacts with c-Jun in Kasumi-1 cells. The c-Jun–specific antibody was used for IP and the anti-ETO antibody was used for western blotting. **P < .01.